OAC SEC filings, in plain English
Everything Oaktree Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Hims & Hers reported Q2 2026 revenue of $753.2M (up 38% YoY) but swung to a net loss of $86.3M from $42.5M net income in Q2 2025, driven by a $968.5M Eucalyptus acquisition in June 2026 and $38.1M in restructuring charges related to its US weight loss offering. Goodwill surged from $278.3M to $1.1B and deferred acquisition payables reached $703M due to the Eucalyptus deal. Why it matters: The post-SPAC entity is aggressively expanding via M&A (Eucalyptus, YourBio, Zava, Medici) funded by convertible notes ($1.37B outstanding) and deferred payments, but profitability has deteriorated with a $178.4M net loss for H1 2026. A $62.5M legal contingency accrual and significant deferred acquisition obligations create near-term cash flow pressure.
What changed: Oaktree Acquisition Corp. (OAC) filed an 8-K on August 10, 2026, reporting Q2 and H1 2026 financial results for the post-combination entity (Hims & Hers Health). Revenue grew to $753.2 million in Q2 2026 from $544.8 million in Q2 2025, while the company swung to a net loss of $86.3 million from net income of $42.5 million in the prior-year quarter. Why it matters: The filing shows the de-SPAC entity is growing revenue rapidly but experiencing deteriorating profitability, with operating expenses outpacing revenue growth and a net loss of $178.4 million for H1 2026. The company also recorded $47.5 million in legal contingencies in Q2, signaling potential regulatory or litigation risk.
What changed: Hims & Hers Health, Inc., the Oaktree Acquisition Corp. successor, said that on July 13, 2026 Irene Becklund gave notice she will resign as Chief Accounting Officer and Principal Accounting Officer effective October 9, 2026. The filing states the resignation is not the result of any dispute over accounting principles or practices, financial statements or disclosures. She has been Chief Accounting Officer since April 2025 and Principal Accounting Officer since November 2021, and an advisory agreement effective October 10, 2026 keeps her supporting the company until July 10, 2027. Why it matters: Accounting officer departures matter mainly for what they might signal, and the filing forecloses the usual concern: no disagreement over accounting principles, statements or disclosures. The nine-month advisory agreement running to July 2027 further indicates an orderly handover rather than a rupture, since a company in an accounting dispute does not retain the departing officer. No trust, redemption or deadline from the former OAC vehicle is affected; the transition window runs nearly three months.
What changed: Hims & Hers Health, Inc., the Oaktree Acquisition Corp. successor, said that on July 1, 2026 subsidiaries XeCare LLC and Apostrophe Pharmacy LLC entered a Master Receivables Purchase Agreement with JPMorgan Chase Bank, under which they may offer eligible receivables for cash at balance less a purchase discount, with the purchaser free to decline. The limit is $400,000,000 and the initial term 364 days, extendable by agreement. The parent gave a Performance Undertaking guaranteeing the sellers' obligations but not collectability. Why it matters: A $400 million receivables purchase facility converts future collections into immediate cash without adding debt to the balance sheet, which flatters reported leverage while creating an ongoing cost in the purchase discount. The purchaser can decline any offered receivable, so the liquidity is not committed in the way a revolver is. For former OAC holders it signals a business scaling working capital needs fast enough to need a facility of that size.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.